Detalhe da pesquisa
1.
An essential gene signature of breast cancer metastasis reveals targetable pathways.
Breast Cancer Res
; 26(1): 98, 2024 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38867323
2.
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
N Engl J Med
; 385(5): 395-405, 2021 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34320285
3.
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Breast Cancer Res Treat
; 205(2): 227-239, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38273214
4.
Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Int J Mol Sci
; 24(1)2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36614261
5.
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Br J Cancer
; 126(3): 456-463, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34754095
6.
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Breast Cancer Res
; 23(1): 112, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34906198
7.
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
Br J Cancer
; 124(11): 1795-1802, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762716
8.
Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
Br J Cancer
; 122(12): 1744-1746, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32336753
9.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(3): 339-351, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30795951
10.
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.
Ann Surg
; 269(6): 1163-1169, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31082916
11.
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Breast Cancer Res Treat
; 206(2): 441, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704775
12.
Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
Ann Surg Oncol
; 26(13): 4274-4283, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31452052
13.
Volume Computed Tomography Perfusion Imaging: Evaluation of the Significance in Oncologic Follow-up of Metastasizing Renal Cell Carcinoma in the Early Period of Targeted Therapy - Preliminary Results.
J Comput Assist Tomogr
; 43(3): 493-498, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30762651
14.
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
BMC Cancer
; 18(1): 1074, 2018 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30400780
15.
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet
; 386(9992): 433-43, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26040499
16.
Circulating tumor cells: from bench to bedside.
Annu Rev Med
; 64: 31-44, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23092385
17.
Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.
BMC Cancer
; 15: 1027, 2015 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26715527
18.
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Mod Pathol
; 27(6): 906-15, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24309322
19.
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.
Mol Oncol
; 2024 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38867388
20.
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Breast Care (Basel)
; 19(1): 1-9, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38384488